AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
EU approves Nvidia’s $700M acquisition of Israeli startup Run:ai
2
Israeli tech’s top 10 funding rounds of 2024: Wiz sets another record
3
Michael Levitt Analysis: Corona Is Slowing Down, Humanity Will Survive
4
The Wiz of GenAI security? “Lasso has the potential to be a once-in-a-decade company in cyber”
5
Israel will "experience a 'baby boom' of innovation" in 2025, says RUNI Ventures
More news

Marius Nacht

7 stories about Marius Nacht
מריוס נכט 1

Life Sciences Venture Fund aMoon Raises $600 Million for Second Fund, Report Says

09.01.19|Hagar Ravet
The Israel-based firm first announced in April it was raising a second fund with a hard cap of $750 million
אינטל קריית גת

CTech’s Tuesday Roundup of Israeli Tech News

01.05.18|CTech
Permira to Buy Cisco’s Video Unit for $1 Billion. Intel to receive $380 million grant from Israel for expanding local chip manufacturing
מריוס נכט 1

Marius Nacht Invests in Swiss Mobile Banking Startup Numbrs

01.05.18|CTech
Numbrs has developed a mobile banking app that aggregates bank accounts and credit card data into a personalized financial service
מוסף 50 הסטארטאפים המבטיחים איור מייסדי צ'ק פוינט גיל שויד ו מריוס נכט

Entrepreneurship Will Continue to Drive Israel’s Economy Forward

18.04.18|Gil Shwed and Marius Nacht
As long as Israeli entrepreneurs go on to translate ideas into products that make life better, Israel’s economy will continue to grow, write Check Point’s co-founders Gil Shwed and Marius Nacht
מריוס נכט 2

Venture Capital Firm aMoon Aims to Raise $500 Million or More For a Second Fund

17.04.18|Lilach Baumer
Established in 2016, aMoon invests in life sciences and healthcare companies, with a focus on Israeli tech
מריוס נכט 1

Founder Offloaded $540 Million Worth of Check Point Stock in 2017

08.02.18|Dror Reich
Marius Nacht, who serves as the information security’s firm chairman, is investing in several life sciences companies
מריוס נכט 1

Check Point Founder Invests in Clinical Stage Company Regenera Pharma

02.01.18|Dror Reich
The company intends to use the funding for a phase 3 clinical trial of its drug for sudden vision loss
Previous Articles